Drug Licensing

Business

Dolby Laboratories Surpasses Expectations in Q1 2026, Driven by Automotive and Streaming Growth

Dolby Laboratories (NYSE: DLB) kicked off fiscal 2026 with robust first-quarter results, exceeding its own revenue and earnings forecasts. The audio-visual technology leader credits strong deal timing and highlighted significant momentum in automotive, television, and mobile partnerships, including expanded ties with Qualcomm and major social media platforms.

Business

GSK Bolsters Pipeline with RAPT Buy, Expands RSV Vaccine to All Adults in Europe

GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.

Business

Cardinal Health Shares Surge on Strong Earnings, But Valuation Questions Loom

Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.

Business

Regeneron's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.

Business

Target Doubles Down on Beauty: 3,000+ New Products and Store Revamps Signal Strategic Shift

Target is launching its largest-ever spring beauty collection, introducing over 3,000 new, predominantly budget-friendly items alongside redesigned in-store experiences and key leadership appointments, signaling a major strategic push to capture market share in the lucrative beauty sector.

Business

Qualcomm's Strategic Pivot: From Mobile Dominance to AI at the Edge

Qualcomm is aggressively diversifying its business beyond smartphones, forging new partnerships in drone security and legal tech to establish its Snapdragon platform as a cornerstone for on-device AI and edge computing.